The treatment of colorectal carcinoma
presents many challenges to the clinician. Among those are the presence of
intrinsic or the development of acquired drug resistance, the aggressive nature
of the disease, and (most notably) the limited number of treatment options.[1-3]
Although fluorouracil (5-FU) has been the mainstay of treatment for colorectal
cancer for 4 decades, as a single agent it is associated with only a 10% to 15%
objective response rate. Patients treated with
5-FU can expect to achieve a median survival of about 10 months.[4-6]
The addition of folinic acid, also known as leucovorin,
increases the response rate, but does not improve the overall median survival
regardless of delivery as bolus 5-FU/leucovorin or as a continuous or short-term
(24- to 48-hour) infusion.[7-11] While regimens consisting of short-term
5-FU with high-dose leucovorin have acceptable tolerability and are widely used
for the treatment of colorectal cancer, especially in Europe, the fact that the
median survival reported in most trials using these regimens is in the range of
9 to 14 months has prompted the search for alternative approaches to
One of the more promising new treatment options for patients
with metastatic colorectal cancer is oxaliplatin (Eloxatin), a third-generation
platinum derivative with a unique mechanism of action.[3,12,13] Oxaliplatin is
among the few drugs that have activity against human colorectal cancers. In
vitro, human tumor xenograft, and clinical studies indicate that it is
synergistic with 5-FU and leucovorin.[3,12,13]
Phase II and III clinical trials conducted in Europe show that
the combination of oxaliplatin with 5-FU/leucovorin is effective as first- or second-line treatment for patients with
metastatic colorectal cancer. Objective response rates as first-line treatment
were > 50% and as second-line treatment, ranged between 20% and 45%. However,
the trials comparing triple- drug therapy to 5-FU/leucovorin did not show a
significant advantage in terms of mean duration of survival compared to
5-FU/leucovorin alone. These trials did, however, meet their original goals of
demonstrating a significant improvement in response rate and progression-free
survival. Thus, a number of studies are currently underway in North America that
are exploring various oxaliplatin combination regimens to help determine the
optimal dosage and administration schedule of combination therapy (Table
Rationale and Design
Because of the discovery and development of a number of active
new agents, the treatment of colon and rectal cancer is at a crossroads.
5-FU/leucovorin regimens have been the standard treatment for decades, and a
multitude of regimens using differing doses, sequences, and lengths of drug
delivery (ranging from bolus to continuous administration) have been studied. In
addition, several combination regimens of 5-FU/leucovorin plus irinotecan
(CPT-11, Camptosar) have shown promise, including the weekly schedule of
administration widely known as the Saltz regimen (named after the physician who
developed and initially tested this regimen).
Based on a randomized study comparing 5-FU/leucovorin with
irinotecan plus 5-FU/leucovorin and irinotecan alone, the Oncologic Drugs
Advisory Committee (ODAC) of the US Food and Drug Administration (FDA) approved
the three-drug regimen as first-line therapy of advanced colorectal cancer in
March 2000. The approval was based on an improvement in response rate (from 21%
to 39%) in the two- vs three-drug regimen, and a commensurate improvement in
median survival of 2.2 months (from 12.6 to 14.8 months). When asked if the
Saltz regimen should henceforth be considered the new regimen to which other
agents or multidrug regimens should be compared, ODAC answered in the
affirmative. This had major consequences for ongoing and future trial designs.
The Redesign Process
The North Central Cancer Treatment Group (NCCTG) N9741 study has
undergone several metamorphoses since it first opened in November 1998. It was
originally designed as a four-arm trial comparing three regimens of
5-FU/leucovorin plus irinotecan vs the Mayo/NCCTG regimen control arm:
5-FU at 425 mg/m2 plus leucovorin at 20 mg/m2.
The rationale for using the 5-FU at 425 mg/m2 plus leucovorin at
20 mg/m2 regimen as the control arm was based on a meta-analysis published in
1992 that showed a 23% response rate and a 12-month median survival for the
regimen. This was still the expectation for the overall success rate in the
control group when trial NCCTG N9741 began.
However, one 5-FU/leucovorin regimena 2-g/24-hour infusion of
5-FUwas dropped because of toxicity issues. Shortly after the study opened,
and oxaliplatin became available for US trials, the study was amended (June
1999) to include three oxaliplatin arms. Thus, the NCCTG N9741 trial temporarily
became a six-arm study in which patients were randomized to one of six treatment
regimens: (1) 5-FU/leucovorin (Mayo/NCCTG), (2) 5-FU/leucovorin plus irinotecan
(Saltz simultaneous), (3) 5-FU/leucovorin plus irinotecan (Mayo sequential), (4)
irinotecan plus oxaliplatin (combination), (5) 5-FU/leucovorin plus oxaliplatin (bolus), or (6)
5-FU/leucovorin plus oxaliplatin (infusion).
In June 2000, the study was finally amended because of two
issues. First, the ODAC’s suggestion that the Saltz regimen should be the new
comparator arm in future trials made it necessary to delete the old comparator
arm of 5-FU/leucovorin (Mayo/NCCTG regimenarm 1) from the study. Second, the
third and fifth arms of the study were noted to be associated with excessive
toxicity, including several treatment-related patient deaths. In addition, the
investigators participating in the trial and the leaders of the gastrointestinal
committees from the cooperative groups participating in the trial now felt that
a simpler three-arm trial was a better design. By comparing arms 2, 4, and 6,
the most important variations of these three active agents could be examined
side by side, and results would be available much sooner than would have been
possible with the six-arm trial (Figure 1).
Mayo Sequential Regimen: Mullany and coworkers first
described sequence-dependent synergy in colon cancer xenografts when they noted
that the optimal interval between administration of irinotecan and 5-FU was
about 24 hours. Consequently, a three-drug regimen was developed on the basis of
laboratory studies performed by Fonseca et al at the Mayo Clinic.
This phase I study in 56 patients began initially with the
administration of a very low dose of irinotecan plus
5-FU due to concerns about synergistic diarrhea. Although most of the
patients were refractory to previous therapy, there were 10 partial or minor
responses. Toxicity consisted of the usual diarrhea, neutropenia, and vomiting.
Doses recommended for further testing were irinotecan at 275 mg/m2 administered
on day 1, and 5-FU at 400 mg/m2 plus leucovorin at 20
mg/m2 administered on days
2 to 5.
Because this regimen is repeated every 3 weeks, the dose
intensity of 5-FU and leucovorin is similar to that of the standard Mayo regimen
described by Poon and coworkers, which is given every 4 or 5 weeks. However,
5 of the first 60 patients accrued to this arm died, possibly of
treatment-related causes. Therefore, it appeared unlikely that this regimen
would prove to be superior to the one developed by Saltz and colleagues, and it
was certainly more toxic. Thus, rather than reduce the doses prescribed by this
regimen, the arm was dropped from the trial.
Oxaliplatin Bolus Regimen: In the United States, many
members of the Gastrointestinal (GI) Intergroup and others regarded bolus 5-FU
dosing as the most familiar method by which to administer 5-FU and leucovorin.
Therefore, an oxaliplatin regimen given in concert with bolus 5-FU was included
in this trial. This regimen was based on a European trial in 115 patients who
progressed after being treated with a regimen of 5-FU plus leucovorin
(unpublished data on file, Sanofi-Synthelabo). Oxaliplatin at 130 mg/m2 was
administered on day 1, followed by
5-FU at 320 mg/m2 plus leucovorin at 20 mg/m2 on days 1 to 5. (This regimen was
repeated every 3 weeks.)
Although the response rate in the original report was 13%, this
was a second-line regimen and therefore, was felt to have demonstrated
sufficient activity to merit further testing. Both the median time to
progression (4.3 months) and median survival (10.1 months) were similar to the
rates reported with other second-line regimens. The main toxicities included
nausea, neutropenia, and neuropathy.
Early in the NCCTG N9741 trial, after about 25 patients had
received this regimen, three deaths occurred due to toxicity. All the patients
developed fatigue, neutropenia, and dehydration, and died within 1 or 2 weeks
following treatment. Representatives of the National Cancer Institute (NCI), the
cooperative groups participating in the trial, and patient representatives held
a meeting to discuss these reports. As a result, the doses of both oxaliplatin
and 5-FU were reduced.
Patients in the oxaliplatin bolus regimen arm of the N9741 trial
then began to receive oxaliplatin at 100 mg/m2 on day 1, followed by 5-FU at 280
mg/m2 plus leucovorin at 20 mg/m2 on days 1 to 5. When two additional
treatment-related deaths were observed at the reduced dose level, this arm of
the trial was dropped.
1. Gorlick R, Bertino JR: Drug resistance in colon cancer. Semin
Oncol 26:606-611, 1999.
2. Van Cutsem E, Milano G, Pritchard DM, et al: New directions
in the treatment of colorectal cancer: A look to the future. Eur J Cancer
3. Wiseman LR, Adkins JC, Plosker GL, et al: Oxaliplatin. A
review of its use in the management of metastatic colorectal cancer. Drugs Aging
4. Köhne-Wömpner CH, Schmoll HJ, Hurstrick A, et al:
Chemotherapeutic strategies in metastatic colorectal cancer: An overview of
current clinical trials. Semin Oncol 19:105-125, 1992.
5. Van Triest B, van Groeningen CJ, Pinedo HM: Current
chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J
Cancer 31a:1193-1197, 1995.
6. Bleiberg H: Role of chemotherapy for advanced colorectal
cancer: New opportunities. Semin Oncol 23:42-50, 1996.
7. Lokich J, Ahlgreen J, Gullo J, et al: Prospective randomized
comparison of continuous infusion of fluorouracil with a conventional bolus
schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program
study. J Clin Oncol 7:425-432, 1989.
8. Ardalan B, Chua L, Tiang E, et al: A phase II of weekly
24-hour infusion with high-dose fluorouracil with leucovorin in colorectal
cancer. J Clin Oncol 9:625-630, 1991.
9. Advanced Colorectal Cancer Meta-Analysis Project: Modulation
of fluorouracil with leucovorin in patients with advanced colorectal cancer:
Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
10. De Gramont A, Bosset JF, Milan C, et al: Randomized trial
comparing monthy low-dose leucovorin and fluorouracil bolus plus continuous
infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol
11. Meta-Analysis Group in Cancer: Efficacy of intravenous
continuous infusion of fluorouracil compared with bolus administration in
advanced colorectal cancer. J Clin Oncol 16:301-308, 1998.
12. Levi F, Metzger G, Massari C, et al: Oxaliplatin.
Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1-21,
13. Cvitkovic E, Bekradda M: Oxaliplatin: A new therapeutic
option in colorectal cancer. Semin Oncol 26:647-662, 1999.
14. Saltz LD, Cox JV, Blanke C, et al: Irinotecan plus
fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med
15. Saltz L, Kantowitz J, Kemeny N, et al: A phase I clinical
and pharmacological trial of irinotecan, 5-fluorouracil, and leucoovrin in
patients with advanced solid tumors. J Clin Oncol 14:2959-2967, 1996.
16. Parnes HL, Tait N, Conley B, et al: A phase I trial of
CPT-11, weekly bolus 5-FU, and leucovorin in patients with metastatic cancer.
Oncol Rep 2:1131-1134, 1995.
17. Saltz LB, Locker PK, Pirotta N, et al: Weekly irinotecan
(CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU
in patients (PTS) with previously untreated metastatic colorectal cancer (CRC)
(abstract 898). Proc Am Soc Clin Oncol 18:233a, 1999.
18. Mullany S, Svingen PA, Kaufmann SH, et al: Effect of adding
the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to
5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced
cytotoxicity. Cancer Chemother Pharmacol 42:391-399, 1998.
19. Fonseca R, Goldberg RM, Erlichman C, et al: Phase I study of
the combination of CPT-11/5-FU and leucovorin (LV) (abstract 781). Proc Am Soc
Clin Oncol 17:203a, 1998.
20. Alberts S, Goldberg RM, Fonseca R, et al: Phase I study of
CPT-11/5-FU and leucovorin (LV) in advanced cancer (abstract 778). Proc Am Soc
Clin Oncol 18:202a, 1999.
21. Poon MA, O’Connell MJ, Moertel CG, et al: Biochemical
modulation of fluorouracil: Evidence of significant improvement of survival and
quality of life in patients with advanced colorectal carcinoma. J Clin Oncol
22. De Gramont A, Figer A, Seymour M, et al: Leucovorin and
fluorouracil with or without oxaliplatin as first-line treatment in advanced
colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
23. Wasserman E, Cuvier C, Lokiec F, et al: Combination of
oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of
two independent phase I studies with pharmacokinetics. J Clin Oncol
24. Wasserman E, Goldwasser F, Ouldkaci M, et al:
CPT-11/oxaliplatin (L-OHP) every 3 weeks: An active combination in colorectal
cancer (CRC) (abstract 2190). Proc Am Acad Cancer Res 39:321a, 1998.
25. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial
of irinotecan plus supportive care to supportive care alone after fluourouracil
failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418,
26. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable
liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg
224: 509-520, 1996.
27. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial
infusion of chemotherapy after resection of hepatic metastases from colorectal
cancer. N Engl J Med 341:2039-2048, 1999.